Debiopharm, a Switzerland-based, global biopharmaceutical company, announced on Wednesday that it has dosed its first patient in its first-in-human, phase 1/2 study, GaLuCi for its CA IX-targeted radiopharmaceutical program.
The first subject was screened and dosed at the Australia-based Peter MacCallum Cancer Centre.
This multicenter international trial, evaluating a radioligand theranostic pair will be carried out in three stages: Part A to confirm the safety and reliability of Debio 0328 in detecting CA IX-expressing solid tumours, Part B to assess escalating doses of the therapeutic agent, Debio 0228 in patients, whose tumours show high uptake of Debio 0328 and finally, based on the recommended dose from part B, Part C will further assess safety and preliminary efficacy in selected tumour types.
The company said that Debio 0228/0328 is currently, the only peptide-based theranostic pair targeting CA IX in clinical development, with pan-tumour potential, and developed first for patients with advanced cancers such as renal, pancreatic, and colorectal. It leverages a theranostic approach to identify and deliver radiation to diseased tissues, allowing the imaging-based pre-identification of patients who have the target proteins necessary to respond to the targeted radioligand.
Chroma Medicine names new director
Medivir to present promising Fostrox data for liver lancer at ESMO Congress
TME Pharma to present NOX-a12 glioblastoma trial results at ESMO Congress 2024
Full-Life Technologies signs licence agreement with SK Biopharmaceuticals
Hoth Therapeutics adds three centres to clinical trial for cancer patients
SFA Therapeutics names new chief operating officer
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation